187.15
-0.65(-0.35%)
Currency In USD
| Previous Close | 187.8 |
| Open | 187.4 |
| Day High | 189.29 |
| Day Low | 185.85 |
| 52-Week High | 205.97 |
| 52-Week Low | 121.05 |
| Volume | 185,809.68 |
| Average Volume | 1.14M |
| Market Cap | 27.61B |
| PE | 20.11 |
| EPS | 9.3 |
| Moving Average 50 Days | 185.56 |
| Moving Average 200 Days | 168.61 |
| Change | -0.77 |
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
GlobeNewswire Inc.
Mar 11, 2026 12:00 PM GMT
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen is a novel antisense oligonucleotide and
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
GlobeNewswire Inc.
Mar 05, 2026 12:30 PM GMT
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investig
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
GlobeNewswire Inc.
Mar 04, 2026 10:05 PM GMT
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– BEDFORD, Mass.